BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of MoCD Type A

Monday, July 13, 2020 1 min read

Key Takeaway: BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of MoCD Type A

Full Press Release Details

BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of MoCD Type A.